Acceptability of Injectable Antiretroviral Therapy in Australian Travelers With HIV

Stephanie Spring¹, Jessica O'Bryan¹, James McMahon^{1

2}, Ian Woolley^{1

2

3}

Affiliations

¹ Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
² Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia.
³ Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Stephanie Spring et al. J Acquir Immune Defic Syndr. 2021.

. 2021 Jan 1;86(1):e13-e15.

doi: 10.1097/QAI.0000000000002501. Epub 2020 Sep 9.

Stephanie Spring¹, Jessica O'Bryan¹, James McMahon^{1

2}, Ian Woolley^{1

2

3}

¹ Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
² Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia.
³ Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

No abstract available

References

1. Salit IE, Sano M, Boggild AK, et al. Travel patterns and risk behaviour of HIV-positive people travelling internationally. Can Med Assoc J. 2005;172:884–888.
1. Elfrink F, van den Hoek A, Sonder GJB. Trends and characteristics among HIV-infected and diabetic travelers seeking pre-travel advice. Trav Med Infect Dis. 2014;12:79–83.
1. Sherrard A, McCarthy A. Travel patterns and health risks for patients infected with HIV. Trav Med Infect Dis. 2009;7:291–295.
1. Margolis DA, Gonzalez-Garcia J, Stellbrink H, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499–1510.
1. Orkin C, Arasteh K, Hernández-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124–1135.